Eintrag weiter verarbeiten
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Clinical Cancer Research, 21, 2015, 2, S. 357-364 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Lee, Keun-Wook Lee, Sung Sook Kim, Sang-Bae Sohn, Bo Hwa Lee, Hyun-Sung Jang, Hee-Jin Park, Yun-Yong Kopetz, Scott Kim, Sung Soo Oh, Sang Cheul Lee, Ju-Seog Lee, Keun-Wook Lee, Sung Sook Kim, Sang-Bae Sohn, Bo Hwa Lee, Hyun-Sung Jang, Hee-Jin Park, Yun-Yong Kopetz, Scott Kim, Sung Soo Oh, Sang Cheul Lee, Ju-Seog |
|---|---|
| author |
Lee, Keun-Wook Lee, Sung Sook Kim, Sang-Bae Sohn, Bo Hwa Lee, Hyun-Sung Jang, Hee-Jin Park, Yun-Yong Kopetz, Scott Kim, Sung Soo Oh, Sang Cheul Lee, Ju-Seog |
| spellingShingle |
Lee, Keun-Wook Lee, Sung Sook Kim, Sang-Bae Sohn, Bo Hwa Lee, Hyun-Sung Jang, Hee-Jin Park, Yun-Yong Kopetz, Scott Kim, Sung Soo Oh, Sang Cheul Lee, Ju-Seog Clinical Cancer Research Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients Cancer Research Oncology |
| author_sort |
lee, keun-wook |
| spelling |
Lee, Keun-Wook Lee, Sung Sook Kim, Sang-Bae Sohn, Bo Hwa Lee, Hyun-Sung Jang, Hee-Jin Park, Yun-Yong Kopetz, Scott Kim, Sung Soo Oh, Sang Cheul Lee, Ju-Seog 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-14-1374 <jats:title>Abstract</jats:title> <jats:p>Purpose: Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed in many cancers, including colorectal cancer. We investigated whether activation of YAP1 is significantly associated with prognosis or treatment outcomes in colorectal cancer.</jats:p> <jats:p>Experimental Design: A gene expression signature reflecting YAP1 activation was identified in colorectal cancer cells, and patients with colorectal cancer were stratified into two groups according to this signature: activated YAP1 colorectal cancer (AYCC) or inactivated YAP1 colorectal cancer (IYCC). Stratified patients in five test cohorts were evaluated to determine the effect of the signature on colorectal cancer prognosis and response to cetuximab treatment.</jats:p> <jats:p>Results: The activated YAP1 signature was associated with poor prognosis for colorectal cancer in four independent patient cohorts with stage I–III disease (total n = 1,028). In a multivariate analysis, the impact of the YAP1 signature on disease-free survival was independent of other clinical variables [hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.25–2.13; P &lt; 0.001]. In patients with stage IV colorectal cancer and wild-type KRAS, IYCC patients had a better disease control rate and progression-free survival (PFS) after cetuximab monotherapy than did AYCC patients; however, in patients with KRAS mutations, PFS duration after cetuximab monotherapy was not different between IYCC and AYCC patients. In multivariate analysis, the effect of YAP1 activation on PFS was independent of KRAS mutation status and other clinical variables (HR, 1.82; 95% CI, 1.05–3.16; P = 0.03).</jats:p> <jats:p>Conclusions: Activation of YAP1 is highly associated with poor prognosis for colorectal cancer and may be useful in identifying patients with metastatic colorectal cancer resistant to cetuximab. Clin Cancer Res; 21(2); 357–64. ©2014 AACR.</jats:p> Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-14-1374 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE0LTEzNzQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE0LTEzNzQ |
| institution |
DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
American Association for Cancer Research (AACR), 2015 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2015 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
lee2015significantassociationofoncogeneyap1withpoorprognosisandcetuximabresistanceincolorectalcancerpatients |
| publishDateSort |
2015 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_unstemmed |
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_full |
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_fullStr |
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_full_unstemmed |
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_short |
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_sort |
significant association of oncogene yap1 with poor prognosis and cetuximab resistance in colorectal cancer patients |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-14-1374 |
| publishDate |
2015 |
| physical |
357-364 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Purpose: Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed in many cancers, including colorectal cancer. We investigated whether activation of YAP1 is significantly associated with prognosis or treatment outcomes in colorectal cancer.</jats:p>
<jats:p>Experimental Design: A gene expression signature reflecting YAP1 activation was identified in colorectal cancer cells, and patients with colorectal cancer were stratified into two groups according to this signature: activated YAP1 colorectal cancer (AYCC) or inactivated YAP1 colorectal cancer (IYCC). Stratified patients in five test cohorts were evaluated to determine the effect of the signature on colorectal cancer prognosis and response to cetuximab treatment.</jats:p>
<jats:p>Results: The activated YAP1 signature was associated with poor prognosis for colorectal cancer in four independent patient cohorts with stage I–III disease (total n = 1,028). In a multivariate analysis, the impact of the YAP1 signature on disease-free survival was independent of other clinical variables [hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.25–2.13; P &lt; 0.001]. In patients with stage IV colorectal cancer and wild-type KRAS, IYCC patients had a better disease control rate and progression-free survival (PFS) after cetuximab monotherapy than did AYCC patients; however, in patients with KRAS mutations, PFS duration after cetuximab monotherapy was not different between IYCC and AYCC patients. In multivariate analysis, the effect of YAP1 activation on PFS was independent of KRAS mutation status and other clinical variables (HR, 1.82; 95% CI, 1.05–3.16; P = 0.03).</jats:p>
<jats:p>Conclusions: Activation of YAP1 is highly associated with poor prognosis for colorectal cancer and may be useful in identifying patients with metastatic colorectal cancer resistant to cetuximab. Clin Cancer Res; 21(2); 357–64. ©2014 AACR.</jats:p> |
| container_issue |
2 |
| container_start_page |
357 |
| container_title |
Clinical Cancer Research |
| container_volume |
21 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348696470355976 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:15:16.455Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Significant+Association+of+Oncogene+YAP1+with+Poor+Prognosis+and+Cetuximab+Resistance+in+Colorectal+Cancer+Patients&rft.date=2015-01-15&genre=article&issn=1557-3265&volume=21&issue=2&spage=357&epage=364&pages=357-364&jtitle=Clinical+Cancer+Research&atitle=Significant+Association+of+Oncogene+YAP1+with+Poor+Prognosis+and+Cetuximab+Resistance+in+Colorectal+Cancer+Patients&aulast=Lee&aufirst=Ju-Seog&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-14-1374&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348696470355976 |
| author | Lee, Keun-Wook, Lee, Sung Sook, Kim, Sang-Bae, Sohn, Bo Hwa, Lee, Hyun-Sung, Jang, Hee-Jin, Park, Yun-Yong, Kopetz, Scott, Kim, Sung Soo, Oh, Sang Cheul, Lee, Ju-Seog |
| author_facet | Lee, Keun-Wook, Lee, Sung Sook, Kim, Sang-Bae, Sohn, Bo Hwa, Lee, Hyun-Sung, Jang, Hee-Jin, Park, Yun-Yong, Kopetz, Scott, Kim, Sung Soo, Oh, Sang Cheul, Lee, Ju-Seog, Lee, Keun-Wook, Lee, Sung Sook, Kim, Sang-Bae, Sohn, Bo Hwa, Lee, Hyun-Sung, Jang, Hee-Jin, Park, Yun-Yong, Kopetz, Scott, Kim, Sung Soo, Oh, Sang Cheul, Lee, Ju-Seog |
| author_sort | lee, keun-wook |
| container_issue | 2 |
| container_start_page | 357 |
| container_title | Clinical Cancer Research |
| container_volume | 21 |
| description | <jats:title>Abstract</jats:title> <jats:p>Purpose: Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed in many cancers, including colorectal cancer. We investigated whether activation of YAP1 is significantly associated with prognosis or treatment outcomes in colorectal cancer.</jats:p> <jats:p>Experimental Design: A gene expression signature reflecting YAP1 activation was identified in colorectal cancer cells, and patients with colorectal cancer were stratified into two groups according to this signature: activated YAP1 colorectal cancer (AYCC) or inactivated YAP1 colorectal cancer (IYCC). Stratified patients in five test cohorts were evaluated to determine the effect of the signature on colorectal cancer prognosis and response to cetuximab treatment.</jats:p> <jats:p>Results: The activated YAP1 signature was associated with poor prognosis for colorectal cancer in four independent patient cohorts with stage I–III disease (total n = 1,028). In a multivariate analysis, the impact of the YAP1 signature on disease-free survival was independent of other clinical variables [hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.25–2.13; P &lt; 0.001]. In patients with stage IV colorectal cancer and wild-type KRAS, IYCC patients had a better disease control rate and progression-free survival (PFS) after cetuximab monotherapy than did AYCC patients; however, in patients with KRAS mutations, PFS duration after cetuximab monotherapy was not different between IYCC and AYCC patients. In multivariate analysis, the effect of YAP1 activation on PFS was independent of KRAS mutation status and other clinical variables (HR, 1.82; 95% CI, 1.05–3.16; P = 0.03).</jats:p> <jats:p>Conclusions: Activation of YAP1 is highly associated with poor prognosis for colorectal cancer and may be useful in identifying patients with metastatic colorectal cancer resistant to cetuximab. Clin Cancer Res; 21(2); 357–64. ©2014 AACR.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-14-1374 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE0LTEzNzQ |
| imprint | American Association for Cancer Research (AACR), 2015 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2015 |
| institution | DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T18:15:16.455Z |
| match_str | lee2015significantassociationofoncogeneyap1withpoorprognosisandcetuximabresistanceincolorectalcancerpatients |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 357-364 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Lee, Keun-Wook Lee, Sung Sook Kim, Sang-Bae Sohn, Bo Hwa Lee, Hyun-Sung Jang, Hee-Jin Park, Yun-Yong Kopetz, Scott Kim, Sung Soo Oh, Sang Cheul Lee, Ju-Seog 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-14-1374 <jats:title>Abstract</jats:title> <jats:p>Purpose: Activation of YAP1, a novel oncogene in the Hippo pathway, has been observed in many cancers, including colorectal cancer. We investigated whether activation of YAP1 is significantly associated with prognosis or treatment outcomes in colorectal cancer.</jats:p> <jats:p>Experimental Design: A gene expression signature reflecting YAP1 activation was identified in colorectal cancer cells, and patients with colorectal cancer were stratified into two groups according to this signature: activated YAP1 colorectal cancer (AYCC) or inactivated YAP1 colorectal cancer (IYCC). Stratified patients in five test cohorts were evaluated to determine the effect of the signature on colorectal cancer prognosis and response to cetuximab treatment.</jats:p> <jats:p>Results: The activated YAP1 signature was associated with poor prognosis for colorectal cancer in four independent patient cohorts with stage I–III disease (total n = 1,028). In a multivariate analysis, the impact of the YAP1 signature on disease-free survival was independent of other clinical variables [hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.25–2.13; P &lt; 0.001]. In patients with stage IV colorectal cancer and wild-type KRAS, IYCC patients had a better disease control rate and progression-free survival (PFS) after cetuximab monotherapy than did AYCC patients; however, in patients with KRAS mutations, PFS duration after cetuximab monotherapy was not different between IYCC and AYCC patients. In multivariate analysis, the effect of YAP1 activation on PFS was independent of KRAS mutation status and other clinical variables (HR, 1.82; 95% CI, 1.05–3.16; P = 0.03).</jats:p> <jats:p>Conclusions: Activation of YAP1 is highly associated with poor prognosis for colorectal cancer and may be useful in identifying patients with metastatic colorectal cancer resistant to cetuximab. Clin Cancer Res; 21(2); 357–64. ©2014 AACR.</jats:p> Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients Clinical Cancer Research |
| spellingShingle | Lee, Keun-Wook, Lee, Sung Sook, Kim, Sang-Bae, Sohn, Bo Hwa, Lee, Hyun-Sung, Jang, Hee-Jin, Park, Yun-Yong, Kopetz, Scott, Kim, Sung Soo, Oh, Sang Cheul, Lee, Ju-Seog, Clinical Cancer Research, Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients, Cancer Research, Oncology |
| title | Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_full | Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_fullStr | Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_full_unstemmed | Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_short | Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| title_sort | significant association of oncogene yap1 with poor prognosis and cetuximab resistance in colorectal cancer patients |
| title_unstemmed | Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-14-1374 |